More about

Atezolizumab

News
August 03, 2021
2 min read
Save

FDA grants priority review to Tecentriq for early NSCLC

FDA grants priority review to Tecentriq for early NSCLC

The FDA granted priority review to atezolizumab as adjuvant treatment for certain people with non-small cell lung cancer.

News
July 21, 2021
2 min read
Save

Atezolizumab plus bevacizumab safe, effective in malignant peritoneal mesothelioma

Atezolizumab plus bevacizumab safe, effective in malignant peritoneal mesothelioma

Atezolizumab plus bevacizumab appeared well-tolerated and resulted in a 40% objective response rate among patients with malignant peritoneal mesothelioma, according to phase 2 study results published in Cancer Discovery.

News
June 28, 2021
1 min read
Save

Cabozantinib-atezolizumab regimen extends PFS, not OS, in advanced liver cancer

Cabozantinib-atezolizumab regimen extends PFS, not OS, in advanced liver cancer

The combination of cabozantinib and atezolizumab prolonged PFS compared with sorafenib among patients with previously untreated advanced hepatocellular carcinoma, according to topline data released by one of the agent’s manufacturers.

News
June 23, 2021
1 min watch
Save

VIDEO: ‘Important’ IMpower010 trial uses immune checkpoint inhibition as an adjuvant therapy

VIDEO: ‘Important’ IMpower010 trial uses immune checkpoint inhibition as an adjuvant therapy

In this video, Pasi A. Jänne, MD, PhD, spoke with Healio about data from the IMpower010 trial presented at the virtual ASCO Annual Meeting.

News
June 22, 2021
1 min watch
Save

VIDEO: Adjuvant atezolizumab provides DFS benefit in patients with resected NSCLC

VIDEO: Adjuvant atezolizumab provides DFS benefit in patients with resected NSCLC

In this video, Roy Herbst, MD, PhD, spoke with Healio about the practice changing IMpower010 trial presented at the virtual ASCO Annual Meeting.

News
May 24, 2021
3 min read
Save

Atezolizumab regimen fails to extend PFS in newly diagnosed ovarian cancer

Atezolizumab regimen fails to extend PFS in newly diagnosed ovarian cancer

The addition of atezolizumab to chemotherapy and bevacizumab failed to significantly prolong PFS for women with newly diagnosed stage III or stage IV epithelial ovarian cancer, according to a phase 3 study in Journal of Clinical Oncology.

News
May 20, 2021
3 min read
Save

Adjuvant atezolizumab extends DFS in early-stage NSCLC

Adjuvant atezolizumab extends DFS in early-stage NSCLC

Atezolizumab after surgery and chemotherapy reduced risk for disease recurrence or death among patients with stage II to stage IIIA non-small cell lung cancer, according to research presented during the virtual ASCO Annual Meeting.

News
March 16, 2021
3 min read
Save

Benefit of atezolizumab regimen may be limited to triple-negative breast cancer subset

Benefit of atezolizumab regimen may be limited to triple-negative breast cancer subset

The benefit of atezolizumab plus nab-paclitaxel in advanced triple-negative breast cancer appeared limited to patients with PD-L1 immune cell-positive tumors, an exploratory analysis of the IMpassion130 trial showed.

News
March 08, 2021
1 min read
Save

Genentech withdraws Tecentriq indication for bladder cancer

Genentech withdraws Tecentriq indication for bladder cancer

Genentech voluntarily withdrew atezolizumab’s indication in the United States for patients with platinum-treated metastatic urothelial carcinoma.

News
February 03, 2021
4 min read
Save

Neoadjuvant atezolizumab induces pathologic response in resectable NSCLC

Neoadjuvant atezolizumab induces pathologic response in resectable NSCLC

Neoadjuvant atezolizumab conferred a 21% major pathologic response rate among patients with resectable stage IB to stage IIIB non-small cell lung cancer.

View more